Citius stock soars 16% as I/ONTAK seen to equal discontinued cancer drug in phase 3 trial
Citius Pharmaceuticals (CTXR) said a phase 3 trial of its drug I/ONTAK, a new formulation of a discontinued drug ONTAK, showed the therapy to be consistent with the prior formulation...
Source: seekingalpha.com